Journal
CURRENT DRUG TARGETS
Volume 14, Issue 13, Pages 1552-1557Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/13894501113149990176
Keywords
Bone mineral density; osteoporosis; rheumatoid arthritis; TNF alpha antagonists
Categories
Ask authors/readers for more resources
Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor alpha (TNF alpha) have been strongly implicated. TNF alpha antagonists have revolutionised the treatment of RA in the recent years. Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline, Scopus and EBSCO databases to evaluate the documented research on the effects of TNF antagonists in RA on bone mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association between TNF alpha antagonists treatment and suppression of bone resorption.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available